{"filing":{"accession_number":"0001193125-26-336751","cik":"0001811063","ticker":"NUVB","company_name":"Nuvation Bio Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d261840d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526336751/d261840d8k.htm"},"events":[{"id":25550,"run_id":23191,"accession_number":"0001193125-26-336751","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Nuvation Bio's Q2 2026 financial results, including $31.7 million in total revenue ($23.2 million in net product revenue for IBTROZI), R\u0026D expenses of $30.7 million, SG\u0026A expenses of $42.6 million, and a net loss of $62.8 million. The press release was issued on August 6, 2026, and is furnished as Exhibit 99.1 to the 8-K under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26413,"accession_number":"0001193125-26-336751","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Nuvation Bio's Q2 2026 financial results, including $31.7 million in total revenue ($23.2 million in net product revenue for IBTROZI), R\u0026D expenses of $30.7 million, SG\u0026A expenses of $42.6 million, and a net loss of $62.8 million. The press release was issued on August 6, 2026, and is furnished as Exhibit 99.1 to the 8-K under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:07.286653+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26413,"accession_number":"0001193125-26-336751","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Nuvation Bio's Q2 2026 financial results, including $31.7 million in total revenue ($23.2 million in net product revenue for IBTROZI), R\u0026D expenses of $30.7 million, SG\u0026A expenses of $42.6 million, and a net loss of $62.8 million. The press release was issued on August 6, 2026, and is furnished as Exhibit 99.1 to the 8-K under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:07.286653+00:00","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-08-06"}]}